CD8A and neoplasm: Two patients with metastatic pancreatic cancer who received CLDN 18.2 CAR-T cell therapy showed significantly increased amount of CD8+ T and Treg cells in peripheral blood, leading to well controlled tumor progression and reduced lung metastases [131].